Advertisement

Inflammatory bowel diseases and the risk of adverse health outcomes: Umbrella review of meta-analyses of observational studies

Published:February 04, 2021DOI:https://doi.org/10.1016/j.dld.2021.01.018

      Abstract

      Background and Aim

      Accumulating evidence indicates a plausible association between inflammatory bowel diseases and the risk of adverse health outcomes. However, the conclusions are inconsistent. We aimed to perform an umbrella review of meta-analyses to appraise and grade the evidence of the association between inflammatory bowel diseases and the risk of adverse health outcomes.

      Methods

      Meta-analyses of observational studies that examined the associations between inflammatory bowel disease and the risk of adverse health outcomes in PubMed, EMBASE, and Web of Science were screened.

      Results

      This umbrella review identified 25 meta-analyses, which yielded 123 effect estimates for 60 unique putative health outcomes. Patients with inflammatory bowel diseases had a higher risk of adverse health outcomes, including multiple cancers, cardiovascular disease, adverse pregnancy outcomes, adverse oral outcomes, and other adverse events. Moreover, inflammatory bowel diseases caused greater harm to health based on the presented evidence. However, none of the evidence was classified as “high” quality, only 15% was classified as “moderate,” and 65% of outcomes were rated as “very low.”

      Conclusion

      Patients with inflammatory bowel diseases had a higher risk of adverse health outcomes and further studies should be conducted to draw firmer conclusions.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Torres J.
        • Mehandru S.
        • Colombel J.F.
        • et al.
        Crohn's disease.
        Lancet. 2017; 389: 1741-1755
        • Ungaro R.
        • Mehandru S.
        • Allen P.B.
        • et al.
        Ulcerative colitis.
        Lancet. 2017; 389: 1756-1770
        • Baumgart D.C.
        • Carding S.R.
        Inflammatory bowel disease: cause and immunobiology.
        Lancet. 2007; 369: 1627-1640
        • Piovani D.
        • Danese S.
        • Peyrin-Biroulet L.
        • et al.
        Environmental Risk Factors for Inflammatory Bowel Diseases: an Umbrella Review of Meta-analyses.
        Gastroenterology. 2019; 157 (.e4): 647-659
        • Ng S.C.
        • Shi H.Y.
        • Hamidi N.
        • et al.
        Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
        Lancet. 2018; 390: 2769-2778
        • Cornish J.
        • Tan E.
        • Teare J.
        • et al.
        A meta-analysis on the influence of inflammatory bowel disease on pregnancy.
        Gut. 2007; 56: 830-837
        • Yuhara H.
        • Steinmaus C.
        • Corley D.
        • et al.
        Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease.
        Aliment Pharmacol Ther. 2013; 37: 953-962
        • Singh S.
        • Nagpal S.J.
        • Murad M.H.
        • et al.
        Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.
        Clin Gastroenterol Hepatol. 2014; 12: 210-218
        • von Roon A.C.
        • Reese G.
        • Teare J.
        • et al.
        The risk of cancer in patients with Crohn's disease.
        Dis Colon Rectum. 2007; 50: 839-855
        • Pedersen N.
        • Duricova D.
        • Elkjaer M.
        • et al.
        Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies.
        Am J Gastroenterol. 2010; 105: 1480-1487
        • Zhu F.
        • Li C.
        • Gong J.
        • et al.
        The risk of Parkinson's disease in inflammatory bowel disease: a systematic review and meta-analysis.
        Dig Liver Dis. 2019; 51: 38-42
        • Wan Q.Y.
        • Zhao R.
        • Wu X.T.
        Older patients with IBD might have higher risk of Parkinson's disease.
        Gut. 2018;
        • B J.S.
        • C H.
        • G A.W.
        • et al.
        AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews.
        J Clin Epidemiol. 2009; 62: 1013-1020
        • G G.
        • A D.O.
        • E A.A.
        • et al.
        GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
        J Clin Epidemiol. 2011; 64: 383-394
        • Canavan C.
        • Abrams K.R.
        • Mayberry J.F.
        Meta-analysis: mortality in Crohn's disease.
        Aliment Pharmacol Ther. 2007; 25: 861-870
        • M M.
        • C J.
        • A P.
        • et al.
        The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study.
        Aliment. Pharmacol. Ther. 2019; 50: 33-39
        • O O.
        • J A.
        • M C.S.
        • et al.
        Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014.
        Gut. 2019; (undefined:undefined)
        • Sun H.H.
        • Tian F.
        Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis.
        Eur J Prev Cardiol. 2018; 25: 1623-1631
        • Huai J.P.
        • Ding J.
        • Ye X.H.
        • et al.
        Inflammatory bowel disease and risk of cholangiocarcinoma: evidence from a meta-analysis of population-based studies.
        Asian Pac J Cancer Prev. 2014; 15: 3477-3482
        • Cao L.
        Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis.
        World J Surg Oncol. 2018; 16: 182
        • Chen M.
        • Yuan C.
        • Xu T.
        An increase in prostate cancer diagnosis during inflammatory bowel disease: a systematic review and meta-analysis.
        Clin Res Hepatol Gastroenterol. 2019;
        • Wang P.
        • Yan H.
        • Wang Z.
        • et al.
        Inflammatory bowel disease and risk of cervical cancer: a meta-analysis.
        Int J Colorectal Dis. 2014; 29: 1023-1024
        • Jess T.
        • Rungoe C.
        • Peyrin-Biroulet L.
        Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies.
        Clin Gastroenterol Hepatol. 2012; 10: 639-645
        • Yuan M.
        • Zhou H.Y.
        • Xiao X.L.
        • et al.
        Inflammatory bowel disease and risk of stroke: a meta-analysis of cohort studies.
        Int J Cardiol. 2016; 202: 106-109
        • Feng W.
        • Chen G.
        • Cai D.
        • et al.
        Inflammatory Bowel Disease and Risk of Ischemic Heart Disease: an Updated Meta-Analysis of Cohort Studies.
        J Am Heart Assoc. 2017; 6
        • A D.P.
        • J E.M.
        • J E.R.
        • et al.
        Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.
        JAMA. 2002; 288: 980-987
        • J J.C.
        • A M.A.
        • T A.M.
        • et al.
        Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study.
        Circulation. 2007; 116: 32-38
        • S K.
        • E D.A.
        • G L.
        • et al.
        C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
        Lancet. 2010; 375: 132-140
        • O'Toole A.
        • Nwanne O.
        • Tomlinson T.
        Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis.
        Dig Dis Sci. 2015; 60: 2750-2761
        • Szafors P.
        • Che H.
        • Barnetche T.
        • et al.
        Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis.
        Osteoporos Int. 2018; 29: 2389-2397
        • K B.
        • P G.
        • I E.B.
        • et al.
        Inflammatory diseases and bone fragility.
        Osteoporosis Int. 2017; 28: 3301-3314
        • H T.
        • A R.M.
        • A K.
        • et al.
        Gut, inflammation and osteoporosis: basic and clinical concepts.
        Gut. 2008; 57: 684-694
        • Papageorgiou S.N.
        • Hagner M.
        • Nogueira A.V.
        • et al.
        Inflammatory bowel disease and oral health: systematic review and a meta-analysis.
        J Clin Periodontol. 2017; 44: 382-393
        • Alinaghi F.
        • Tekin H.G.
        • Burisch J.
        • et al.
        Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease - A systematic review and meta-analysis.
        J Crohns Colitis. 2019;
        • Han J.
        • Liu T.
        • Zhang M.
        • et al.
        The relationship between inflammatory bowel disease and rosacea over the lifespan: a meta-analysis.
        Clin Res Hepatol Gastroenterol. 2019; 43: 497-502
        • Zhang F.M.
        • Xu C.F.
        • Shan G.D.
        • et al.
        Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis.
        J Dig Dis. 2015; 16: 634-641
        • Gu P.
        • Kuenzig M.E.
        • Kaplan G.G.
        • et al.
        Fecal incontinence in inflammatory bowel disease: a systematic review and meta-analysis.
        Inflamm Bowel Dis. 2018; 24: 1280-1290
        • P M.
        • A L.K.
        • H H.
        • et al.
        Mortality in ulcerative colitis and Crohn's disease. A population-based study in Finland.
        J Crohns Colitis. 2012; 6: 524-528
        • O O.
        • J A.
        • M C.S.
        • et al.
        Increased mortality of patients with childhood-onset inflammatory bowel diseases, compared with the general population.
        Gastroenterology. 2019; 156: 614-622
        • M D.K.
        • D K.F.
        • M D.L.
        • et al.
        Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation.
        Clin Gastroenterol Hepatol. 2014; 12 (.e1): 265-273
        • C N.B.
        • J F.B.
        • E K.
        • et al.
        Cancer risk in patients with inflammatory bowel disease: a population-based study.
        Cancer. 2001; 91: 854-862
        • K V.W.
        • T J.
        • E L.
        • et al.
        Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County.
        Clin Gastroenterol Hepatol. 2004; 2: 1088-1095
        • J S.
        • A E.
        • U H.
        • et al.
        Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population?.
        Gut. 2019; 68: 1588-1596
        • G R.
        Chronic ulcerative colitis and colorectal cancer.
        Cancer Lett. 2014; 345: 235-241
        • W A.B.
        • C M.
        • T M.N.
        • et al.
        Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: a cochrane systematic review and meta-analysis.
        Am J Gastroenterol. 2018; 113: 1801-1809
        • T G.
        • Q H.
        • X H.
        • et al.
        Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis.
        Cancer Lett. 2019; 445: 11-23
        • Z J.
        • C M.O.
        • M T.B.
        • et al.
        Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis.
        Am J Transpl. 2016; 16: 3490-3503
        • A K.
        • A G.F.
        • B I.K.
        • et al.
        Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.
        Gut. 2005; 54: 1121-1125
        • A R.S.
        • S P.
        • U N.
        • et al.
        Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients.
        J Crohns Colitis. 2011; 5: 287-294
        • A D.
        • J C.
        • P C.
        • et al.
        Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study.
        Circulation. 2014; 130: 837-844
        • P Z.
        • G K.
        • F S.
        Inflammatory bowel disease and thromboembolism.
        World J Gastroenterol. 2014; 20: 13863-13878
        • C R.
        • N N.
        • A T.J.
        Inflammatory bowel disease and risk of coronary heart disease.
        Trends Cardiovasc Med. 2015; 25: 699-704
        • I R.
        • Y C.S.
        • J P.F.
        • et al.
        Evidence of endothelial dysfunction in patients with inflammatory bowel disease.
        Clin Gastroenterol Hepatol. 2009; 7: 175-182
        • I D.
        • A A.
        • D R.
        • et al.
        Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: a multicenter study in Israel.
        J Crohns Colitis. 2013; 7: 542-550
        • A W.S.
        • J S.C.
        • W S.
        • et al.
        Inflammatory bowel disease in pregnancy: a population-based study of prevalence and pregnancy outcomes.
        BJOG: Int J Obst Gynaecol. 2016; 123: 1862-1870
        • D D.B.
        • M N.
        • R S.S.
        Increased risk of preterm birth for women with inflammatory bowel disease.
        Gastroenterology. 1990; 99: 987-994
        • A V.P.
        • A V.
        • H E.G.
        Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease.
        Birth Defects Res. Part A Clin. Mol. Teratol. 2016; 106: 494-499
        • J A.K.
        • C A.
        • G F.K.
        • et al.
        Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
        Am J Gastroenterol. 2004; 99: 2385-2392
        • Neurath M.
        Current and emerging therapeutic targets for IBD.Nature reviews.
        Gastroenterol Hepatol (N Y). 2017; 14: 269-278
        • Papa A.
        • Tursi A.
        • Danese S.
        • et al.
        Venous thromboembolism in patients with inflammatory bowel disease: the role of pharmacological therapy and surgery.
        J Clin Med. 2020; 9
        • Sarlos P.
        • Szemes K.
        • Hegyi P.
        • et al.
        Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: a Meta-Analysis.
        J Crohns Colitis. 2018; 12: 489-498
        • Kandiel A.
        • Fraser A.G.
        • Korelitz B.I.
        • et al.
        Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.
        Gut. 2005; 54: 1121-1125